Femasys to Showcase Fertility Solutions at ASRM 2025 Scientific Congress & Expo

SAN ANTONIO, Texas — October 16, 2025 — Leads & Copy — Femasys Inc. (NASDAQ: FEMY) will exhibit its fertility solutions at the American Society for Reproductive Medicine (ASRM) 2025 Scientific Congress & Expo, scheduled for October 25-29 at the Henry B. González Convention Center in San Antonio, Texas. The company will be at booth #619.

According to Kathy Lee-Sepsick, CEO and Founder of Femasys, the company is excited to return to ASRM to share its next-generation therapeutic fertility innovation, FemaSeed® Intratubal Insemination. Attendees are encouraged to visit the booth to discuss when Intra-Tubal Insemination (ITI) may be most effective for their patients, explore workflow integration, and how FemaSeed can complement their current offerings. They can also access clinical data and resources to guide conversations with patients, and gain insights from real-world experience with FemaSeed in fertility practice.

FemaSeed is a next-generation artificial insemination solution that enhances natural fertilization by delivering sperm precisely to the fallopian tube. As a first step in the fertility journey, FemaSeed offers a safe, accessible, and cost-effective alternative to intrauterine insemination (IUI). In its pivotal trial, FemaSeed achieved more than double the pregnancy rates of IUI in cases of low male sperm count. It is authorized for use in the U.S., Europe, UK, Canada, Israel, Australia and New Zealand.

The expanded FemaSeed Intratubal Insemination portfolio includes the FemSperm™ Setup Kit, the FemSperm Prep Kit, and the FemSperm Analysis Kit which enable gynecologists to perform sperm preparation and offer FemaSeed Intratubal Insemination directly within their practices. More information on FemaSeed can be found at www.femaseed.com.

The ASRM 2025 Scientific Congress & Expo offers exhibitors and sponsors the opportunity to connect with over 5,500 leaders in reproduction, infertility, contraception, reproductive surgery, menopause, and embryology. The program extends beyond addressing infertility to encompass all aspects of family building and reproductive health.

If you are attending ASRM, be sure to stop by the Femasys booth #619 and tag us on social channels using the hashtag #ASRM2025.

Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Joshua Taustein, Dresner Corporate Services, (847) 308-5168, jtaustein@dresnerco.com

Source: Femasys Inc.

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.